BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1047 related articles for article (PubMed ID: 3553213)

  • 1. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy.
    Collen D
    J Cell Biochem; 1987 Feb; 33(2):77-86. PubMed ID: 3553213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrin-specific thrombolytic agents.
    Collen D
    Klin Wochenschr; 1988; 66 Suppl 12():15-23. PubMed ID: 3126344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrin-specific thrombolytic agents.
    Collen D
    Ann Biol Clin (Paris); 1988; 46(3):195-200. PubMed ID: 3044205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
    Collen D; Lijnen HR
    Thromb Haemost; 1995 Jul; 74(1):167-71. PubMed ID: 8578451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
    Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
    Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coronary thrombolysis with clot-selective plasminogen activators.
    Collen D; Bounameaux H
    Herz; 1986 Feb; 11(1):9-15. PubMed ID: 3082731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrin-specific thrombolytic agents.
    Collen D
    Schweiz Med Wochenschr; 1987 Nov; 117(46):1791-8. PubMed ID: 3122317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
    Dewerchin M; Vandamme AM; Holvoet P; De Cock F; Lemmens G; Lijnen HR; Stassen JM; Collen D
    Thromb Haemost; 1992 Aug; 68(2):170-9. PubMed ID: 1412163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential approaches for therapeutic intervention of thrombosis by fibrinolytic agents.
    Collen D
    Semin Thromb Hemost; 1988 Jan; 14(1):95-9. PubMed ID: 3127886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue-type plasminogen activator.
    Lijnen HR; Collen D
    Ann Biol Clin (Paris); 1987; 45(2):198-201. PubMed ID: 2956911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New thrombolytic agents in myocardial infarction].
    Charbonnier B; Lang M; Brochier M
    Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The nature of synergy between tissue-type and single chain urokinase-type plasminogen activators.
    Fry ET; Mack DL; Sobel BE
    Thromb Haemost; 1989 Nov; 62(3):909-16. PubMed ID: 2512679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of new thrombolytic substances].
    Zeymer U; Neuhaus KL
    Herz; 1994 Dec; 19(6):314-25. PubMed ID: 7843688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
    Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
    Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
    Munkvad S
    Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [t-PA in thrombolytic therapy of acute myocardial infarct].
    Rutsch W; Schmutzler H
    Herz; 1994 Dec; 19(6):336-52. PubMed ID: 7843690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Biochemical and physiologic principles of tissue-type plasminogen activator].
    Lill H
    Z Gesamte Inn Med; 1987 Sep; 42(17):478-86. PubMed ID: 3120429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The molecular basis of thrombolysis and its clinical application in stroke.
    Murray V; Norrving B; Sandercock PA; Terént A; Wardlaw JM; Wester P
    J Intern Med; 2010 Feb; 267(2):191-208. PubMed ID: 20175866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrinolytic agents: mechanisms of activity and pharmacology.
    Lijnen HR; Collen D
    Thromb Haemost; 1995 Jul; 74(1):387-90. PubMed ID: 8578491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New thrombolytic agents].
    Nguyen G; Samama M
    Ann Biol Clin (Paris); 1987; 45(2):212-8. PubMed ID: 3113300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.